Outlook Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
111 Wood Ave S Unit 100, Iselin, New Jer...Phone Number
(609) 619-3990Website
www.outlooktherapeutics.comRevenue
<$5 MillionStock Symbol
OTLKIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Outlook Therapeutics
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic therapies for retinal diseases. The company specializes in advancing treatments designed to preserve vision and improve outcomes for patients with conditions such as wet age-related macular degeneration and other serious retinal disorders. Through its expertise in biologics, clinical development, and ophthalmology, Outlook Therapeutics aims to deliver high-quality, clinically validated therapies that address unmet needs in retinal care while enhancing accessibility, treatment consistency, and long-term eye health for patients worldwide.Explore more
Outlook Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Outlook Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Outlook Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Outlook Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Outlook Therapeutics
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Outlook Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Outlook Therapeutics has new funding data
Check out if Outlook Therapeutics is spiking on competitors!
Product Launch: Get notified when Outlook Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Click to see if Outlook Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Outlook Therapeutics
Compare insights from companies similar to Outlook Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Outlook Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Outlook Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Outlook Therapeutics.
Outlook Therapeutics financials insights
Gather financial insights about Outlook Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Private Equity
$31M
Corporate Investment
$44M
2016
Stock Offering
$29.8M
2018
Share Placement
$15M
2019
Share Placement
$20M
Stock Offering
$26.2M
2020
Share Placement
$10.2M
2021
Stock Offering
$35M
2022
Debt
$31.8M
Outlook Therapeutics Tech Stack
A closer look at the technologies used by Outlook Therapeutics
See more technologies
Most Recent Scoops
Open Position
Person-Based
Pharmaceuticals
Person-Based
Pharmaceuticals
Person-Based
Pharmaceuticals
Person-Based
Outlook Therapeutics News & Media
Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ONS-5010/LYTENAVA™ for the treatment of neovascular age-related macular degeneration (nAMD).Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
ISELIN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal diseases, today announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8,539,709 shares of its common stock at a purchase price of $0.5855 per share in a registered direct offering priceOutlook Therapeutics Wins Appeal Following Formal Dispute Resolution Process for ONS-5010/LYTENAVA™ (bevacizumab-vikg)
Company plans to resubmit BLA to the FDA in June 2026 Company plans to resubmit BLA to the FDA in June 2026Outlook Therapeutics Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update
ISELIN, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for the second quarter of fiscal year 2026 ended March 31, 2026, and provided a corporate update.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Outlook Therapeutics
Sign Up For FreeTo access detailed company insights
Outlook Therapeutics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic therapies for retinal diseases. The company specializes in advancing treatments designed to preserve vision and improve outcomes for patients with conditions such as wet age-related macular degeneration and other serious retinal disor... Read More
